Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice

Journal of Infection

Volumn 49, Issue 4, 2004, Pages 283-290

  Visnegarwala, Fehmida ^a,c   Maldonado, Mario ^a   Sajja, Prasuna ^a   Minihan, Jennifer L ^a,b   Rodriguez Barradas, Maria C ^a,b   Ong, Oliver ^a   Lahart, Christopher J ^a,c   Hasan, Mirza Qasim ^d   Balasubramanyam, Ashok ^a   White Jr , A Clinton ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HARRIS COUNTY HOSPITAL DISTRICT   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Antiretroviral therapy; Cohort study; HIV dyslipidemia; Lipid lowering drugs

Indexed keywords

ANTIRETROVIRUS AGENT; ATORVASTATIN; CHOLESTEROL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; DRUG WITHDRAWAL; DYSLIPIDEMIA; ETHNIC DIFFERENCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME;

EID: 5044241745     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2003.09.006     Document Type: Article

References (33)

1. Grunfeld C. Kotler D.P. Hamadeh R. Tierney A. Wang J. Pierson R.N. Hypertriglyceridemia in the acquired immunodeficiency syndrome Am J Med 86 1 1989 27-31
2. Dube M.P. Sprecher D. Henry W.K. Aberg J.A. Torriani F.J. Hodis H.N. et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group Clin Infect Dis 31 5 2000 1216-1224
3. Carr A. Samaras K. Thorisdottir A. Kaufmann G.R. Chisholm D.J. Cooper D.A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study Lancet 353 9170 1999 2093-2099
4. Visnegarwala F. Krause K.L. Musher D.M. Severe diabetes associated with protease inhibitor therapy Ann Intern Med 127 10 1997 947
5. Purnell J.Q. Zambon A. Knopp R.H. Pizzuti D.J. Achari R. Leonard J.M. et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects AIDS 14 1 2000 51-57
6. Moyle G.J. Lloyd M. Reynolds B. Baldwin C. Mandalia S. Gazzard B.G. Dietary advice with or without pravastatin for the management of hypercholesterolemia associated with protease inhibitor therapy AIDS 15 12 2001 1503-1508
7. Miller J. Brown D. Amin J. Kent-Hughes J. Law M. Kaldor J. et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia AIDS 16 16 2002 2195-2200
8. Aberg JAZR, Evans S, et al. A prospective multicenter randomized trial comparing the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities. ACTG 5087. In: Program and abstracts of the 40th Annual Meeting of the Infectious Diseases of America; October, 24-27, 2002, Chicago, Illinois. Abstract 26. 2002; 2002.
9. Radford M.J.F.J. How do observational studies expand the evidence base for therapy? JAMA 286 10 2001 1228-1230
10. Balk E.M. Bonis P.A. Moskowitz H. Schmid C.H. Ioannidis J.P. Wang C. et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials JAMA 287 22 2002 2973-2982
11. Michels K.B. Braunwald E. Estimating treatment effects from observational data: dissonant and resonant notes from the SYMPHONY trials JAMA 287 23 2002 3130-3132
12. Benner J.S. Glynn R.J. Mogun H. Neumann P.J. Weinstein M.C. Avorn J. Long-term persistence in use of statin therapy in elderly patients JAMA 288 4 2002 455-461
13. Jackevicius C.A. Mamdani M. Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes JAMA 288 4 2002 462-467
14. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.
15. Baldini F. Di Giambenedetto S. Cingolani A. Murri R. Ammassari A. De Luca A. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study AIDS 14 11 2000 1660-1662
16. Henry K. Melroe H. Huebesch J. Hermundson J. Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities Lancet 352 9133 1998 1031-1032
17. Penzak S.R. Chuck S.K. Stajich G.V. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection Pharmacotherapy 20 9 2000 1066-1071
18. Hewitt R.G.S.M. Esch L.D. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients AIDS 13 1999 868-869
19. Schliefer KWJ, Braitinger D, et al. Efficacy of benzofibrate in the treatment of PI-induced hyperlipidemia-36 week data [abstract WePeB4214]. In: 13th International AIDS Conference. Durban, South Africa, July, 9-14, 2000.
20. Cui Y. Blumenthal R.S. Flaws J.A. Whiteman M.K. Langenberg P. Bachorik P.S. et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality Arch Intern Med 161 11 2001 1413-1419
21. Palacios R. Santos J. Gonzalez M. Ruiz J. Valdivielso P. Marquez M. et al. Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy J Acquir Immune Defic Syndr 31 2 2002 251-253
22. Fichtenbaum C, Gerber J, Rosenkranz S, Segal Y, Blaschke T, Aberg J, et al. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors. Seventh Annual Conference on Retroviruses and Opportunistic Infections, Jan 30-Feb 2, 2000; San Francisco, CA; Abstract No. LB6 LB6.
23. Hsyu P.H. Schultz-Smith M.D. Lillibridge J.H. Lewis R.H. Kerr B.M. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin Antimicrob Agents Chemother 45 12 2001 3445-3450
24. Palacios R. Santos J. Gonzalez M. Ruiz J. Valdivielso P. Marquez M. et al. Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy J Acquir Immune Defic Syndr 30 5 2002 536-537
25. Ridker P.M. Rifai N. Clearfield M. Downs J.R. Weis S.E. Miles J.S. et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 26 2001 1959-1965
26. Shovman O. Levy Y. Gilburd B. Shoenfeld Y. Antiinflammatory and immunomodulatory properties of statins Immunol Res 25 3 2002 271-285
27. Frick M.H. Elo O. Haapa K. Heinonen O.P. Heinsalmi P. Helo P. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 20 1987 1237-1245
28. Sekhar R.V. Jahoor F. White A.C. Pownall H.J. Visnegarwala F. Rodriguez-Barradas M.C. et al. Metabolic basis of HIV-lipodystrophy syndrome Am J Physiol Endocrinol Metab 283 2 2002 E332-E337
29. Martinez E. Garcia-Viejo M.A. Blanco J.L. Bianchi L. Buira E. Conget I. et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy Clin Infect Dis 31 5 2000 1266-1273
30. Ruiz L. Negredo E. Domingo P. Paredes R. Francia E. Balague M. et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1- year prospective follow-up of a multicenter, randomized, controlled study J Acquir Immune Defic Syndr 27 3 2001 229-236
31. Negredo E. Cruz L. Paredes R. Ruiz L. Fumaz C.R. Bonjoch A. et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression Clin Infect Dis 34 4 2002 504-510
32. Surveillance C.D.C. Report notes slowdown in new HIV/AIDS rates AIDS Policy Law 17 5 2002 8
33. Parulkar A.A. Pendergrass M.L. Granda-Ayala R. Lee T.R. Fonesca V.A. Nonhypoglycemic effects of thiazolidinediones Ann Int Med 134 2001 61-71